NCT06052839
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Recruiting
PHASE2Ages 18+InterventionalTreatmentDan ZandbergInvestigator-initiated
~15 participants
Updated 2026-02-09 on ClinicalTrials.gov
What's tested:PembrolizumabCarboplatinPaclitaxel
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
6-month Progression-free Survival (PFS)
Measured over At 6 months
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Dan P Zandberg, MD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- 6-month Progression-free Survival (PFS)At 6 months
Proportion of patients alive and without disease progression at 6 months after starting treatment, per RECIST v1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).